Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

C/Ebpg (CCAAT/Enhancer Binding Protein Gamma) Balances Cytotoxic and Secretory Potential of Natural Killer Cells

Izabela Aparecida Lopes, MSc, Miroslava Kardosova, MSc, Thiago Mantello Bianco, MSc, Adriana Queiroz Arantes, MD, Cleide Araújo Silva, MSc, Priscila Santos Scheucher, PhD, Daniel G. Tenen, MD, Sanghoon Lee, PhD, Eduardo Magalhães Rego, MD PhD, Robert S. Welner, PhD, Meritxell Alberich-Jorda, Lorena Lobo Figueiredo-Pontes, MD PhD

Blood (2018) 132 (Supplement 1): 3721.

https://doi.org/10.1182/blood-2018-99-119389

Published: 2018

Journal Articles

Utilizing Digital Pathology Informatics Algorithms for Diffuse Large B-Cell Lymphoma Subtyping

Jordan S. Goldstein, BS, Sanghoon Lee, Jacob Jordan, David L. Jaye, MD, Christopher Flowers, MD, Lee Cooper, PhD

Blood (2017) 130 (Supplement 1): 4147.

https://doi.org/10.1182/blood.V130.Suppl_1.4147.4147

Published: 2017

Journal Articles

Ibrutinib Significantly Prolonged Survival in a Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: Ibrutinib May be a Potential Adjuvant Agent in the Treatment of BL

Sanghoon Lee, PhD MSc., Changhong Yin, MD MS, Janet Ayello, MS, Erin Morris, RN, Timmy O'Connell, MS, Lauren Harrison, RN, MSN, Carmella van de Ven, MA, Matthew J. Barth, MD, Rodney R. Miles, MD PhD, Paul J. Galardy, MD, Stanton Goldman, MD, Megan S Lim, MD PhD, Michelle L. Hermiston, MD PhD, Linda McAllister-Lucas, MDPhD, Lisa Giulino-Roth, MD, Sherrie L. Perkins, MD PhD, Mitchell S. Cairo, MD

Blood (2015) 126 (23): 5117.

https://doi.org/10.1182/blood.V126.23.5117.5117

Published: 2015

Journal Articles

Ibrutinib Alone and in Combination with Dexamethasone and Carfilzomib Significantly Inhibits Cell Proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): Ibrutinib May be a Future Targeted Agent in Combination Therapy in Patients with PMBL

Sanghoon Lee, PhD MSc., Changhong Yin, MD MS, Janet Ayello, MS, Erin Morris, RN, Lauren Harrison, RN, MSN, Carmella van de Ven, MA, Matthew J. Barth, MD, Rodney R. Miles, MD PhD, Paul J. Galardy, MD, Stanton Goldman, MD, Megan S Lim, MD PhD, Michelle L. Hermiston, MD PhD, Linda McAllister-Lucas, MDPhD, Lisa Giulino-Roth, MD, Sherrie L. Perkins, MD PhD, Mitchell S. Cairo, MD

Blood (2015) 126 (23): 4852.

https://doi.org/10.1182/blood.V126.23.4852.4852

Published: 2015

Journal Articles

Downregulation of DLEU1 Significantly Shortened Survival in a Rituximab-Treated DLEU1 Knockout Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: DLEU1 May Act As a Tumor Suppressor Gene in Pediatric BL

Sanghoon Lee, PhD MSc, Changhong Yin, MD MS, Janet Ayello, MS, Erin Morris, RN, Carmella van de Ven, MA, Mitchell S. Cairo, MD

Blood (2015) 126 (23): 3656.

https://doi.org/10.1182/blood.V126.23.3656.3656

Published: 2015

Journal Articles

Ruxolitinib Significantly Prolongs Survival in Both a Primary Mediastinal B-Cell Lymphoma (PMBL) and Hodgkin Lymphoma (HL) Xenograft NSG Mouse Model: Ruxolitinib May be a Potential Adjuvant Agent in the Treatment of PMBL and of HL

Sanghoon Lee, PhD MSc., Changhong Yin, MD MS, Janet Ayello, MS, Erin Morris, RN, Carmella van de Ven, MA, Mitchell S. Cairo, MD

Blood (2015) 126 (23): 2732.

https://doi.org/10.1182/blood.V126.23.2732.2732

Published: 2015

Journal Articles

Obinutuzumab (GA101) Significantly Inhibits Cell Proliferation and Induces Programmed Cell Death in Primary Mediastinal B-Cell Lymphoma (PMBL): Obinutuzumab May be a Future Targeted Agent for the Treatment of PMBL

Changhong Yin, MS, Sanghoon Lee, PhD MSc., Timmy O'Connell, MS, Janet Ayello, MS, MT(ASCP), Carmella van de Ven, MA, Mitchell S. Cairo, MD

Blood (2014) 124 (21): 4492.

https://doi.org/10.1182/blood.V124.21.4492.4492

Published: 2014

Journal Articles

Exogenous Overexpression Of DLEU1 Significantly Induces Programmed Cell Death and Inhibits Cell Proliferation In Burkitt Lymphoma (BL) and Sensitizes Rituximab (RTX) Resistant BL Cells To RTX Induced Apoptosis

Sanghoon Lee, PhD, MSc, Changhong Yin, MS, Janet Ayello, MS, MT(ASCP), Timmy O'Connell, MS, Carmella van de Ven, MA, Miguel Muniz, AAS, Matthew J. Barth, MD, Mitchell S. Cairo, MD

Blood (2013) 122 (21): 2503.

https://doi.org/10.1182/blood.V122.21.2503.2503

Published: 2013

Journal Articles

Transcription Activator Like Effector Nucleases (TALENs) Mediated CD20 Gene Knockout Burkitt Lymphoma Model

Sanghoon Lee, PhD, MSc, Changhong Yin, MS, Janet Ayello, MS, MT(ASCP), Michael Genualdi, MS, Carmella van de Ven, MA, Mitchell S. Cairo, MD

Blood (2013) 122 (21): 4883.

https://doi.org/10.1182/blood.V122.21.4883.4883

Published: 2013

Journal Articles

Overexpression Of Deleted In Lymphocytic Leukemia 1 (DLEU1) Significantly Induces Programmed Cell Death and Inhibits Cell Proliferation In Primary Mediastinal B-Cell Lymphoma (PMBL): DLEU1 May Be a Tumor Suppressor Gene In a Subset Of Patients With PMBL

Changhong Yin, MS, Tae-Hoon Chung, PhD, Janet Ayello, MS, MT(ASCP), Tae-Hyun Park, MS, Carmella van de Ven, MA, Mitchell S. Cairo, MD, Sanghoon Lee, Ph.D, MSc.

Blood (2013) 122 (21): 3852.

https://doi.org/10.1182/blood.V122.21.3852.3852

Published: 2013

Journal Articles

Sequence-Specific Talens-Induced DLEU1 Gene Disruption Significantly Suppresses Apoptosis and Increases Phosphorylation Of AKT and Ikba In Pediatric Burkitt Lymphoma (PBL): DLEU1 May Act As a Tumor Suppressor Gene In PBL

Sanghoon Lee, PhD, MSc, Changhong Yin, MS, Timmy O'Connell, MS, Janet Ayello, MS, MT(ASCP), Carmella van de Ven, MA, Mitchell S. Cairo, MD

Blood (2013) 122 (21): 1279.

https://doi.org/10.1182/blood.V122.21.1279.1279

Published: 2013

Journal Articles

Obinutuzumab (GA101), a Novel Type II Glycoengineered CD20 Antibody, Significantly Induced Programmed Cell Death In Primary Mediastinal B-Cell Lymphoma (PMBL): Obinutuzumab May Be a Future Potential Targeted Agent For The Treatment Of PMBL

Changhong Yin, MS, Timmy O'Connell, MS, Janet Ayello, MS, MT(ASCP), Carmella vande Ven, MA, Sanghoon Lee, PhD, MSc, Mitchell S. Cairo, MD

Blood (2013) 122 (21): 5146.

https://doi.org/10.1182/blood.V122.21.5146.5146

Published: 2013

Journal Articles

Transcription Activator-Like Effector Nucleases (TALENs)-Mediated Deletion Of MIR17HG In Burkitt Lymphoma Cells Decreases mTOR Pathway Activity and Increases Chemosensitivity

Faye Pais, Ph.D., Sanghoon Lee, Ph.D, MSc., Vladimir Rodic, Matthew J. Barth, MD, Mitchell S. Cairo, MD, Michelle L. Hermiston, MD, PhD, Rodney R. Miles, MD, PhD

Blood (2013) 122 (21): 243.

https://doi.org/10.1182/blood.V122.21.243.243

Published: 2013

Journal Articles

JAK1/JAK2 Inhibitor, Ruxolitinib Inhibits Cell Proliferation and Induces Apoptosis in Hodgkin Lymphomas (HL) and Primary Mediastinal B-Cell Lymphomas (PMBL)

Changhong Yin, MS, Sanghoon Lee, PhD, MSc, Janet Ayello, MS, MT(ASCP), Carmella van de Ven, MA, James Pao, BA, Erin Mulvey, BA, Mitchell S. Cairo, MD

Blood (2012) 120 (21): 4886.

https://doi.org/10.1182/blood.V120.21.4886.4886

Published: 2012

Journal Articles

Overexpression of Deleted Lymphocytic Leukemia 1 (DLEU1) Inhibits Proliferation of Burkitt Lymphoma (BL).

Sanghoon Lee, PhD, MSc, Changhong Yin, MS, Janet Ayello, MS, MT(ASCP), Carmella van de Ven, MA, Charles Biggar, Henry Kwang, BA, Erin Mulvey, BA, James Pao, BA, Mitchell S. Cairo, MD

Blood (2012) 120 (21): 2654.

https://doi.org/10.1182/blood.V120.21.2654.2654

Published: 2012

Journal Articles

Talens-Mediated DLEU1 Gene Silencing in Burkitt Lymphoma (BL): Implication of Lncrna DLEU1 Gene As a Potential Tumor Suppressor Gene in BL.

Sanghoon Lee, PhD, MSc, Changhong Yin, MS, Janet Ayello, MS, MT(ASCP), Carmella van de Ven, MA, Henry Hwang, BA, Charles Biggar, James Pao, BA, Erin Mulvey, BA, Mitchell S. Cairo, MD

Blood (2012) 120 (21): 2403.

https://doi.org/10.1182/blood.V120.21.2403.2403

Published: 2012

Journal Articles

Epigenetic Control of C/EBPa by Distant Synergic Regulatory Elements.

Alexander K Ebralidze, Annalisa Di Ruscio, Sanghoon Lee, Karen O'Brien, Daniel G. Tenen

Blood (2009) 114 (22): 1470.

https://doi.org/10.1182/blood.V114.22.1470.1470

Published: 2009

NARROW

C/Ebpg (CCAAT/Enhancer Binding Protein Gamma) Balances Cytotoxic and Secretory Potential of Natural Killer Cells

Utilizing Digital Pathology Informatics Algorithms for Diffuse Large B-Cell Lymphoma Subtyping

Ibrutinib Significantly Prolonged Survival in a Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: Ibrutinib May be a Potential Adjuvant Agent in the Treatment of BL

Ibrutinib Alone and in Combination with Dexamethasone and Carfilzomib Significantly Inhibits Cell Proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): Ibrutinib May be a Future Targeted Agent in Combination Therapy in Patients with PMBL

Downregulation of DLEU1 Significantly Shortened Survival in a Rituximab-Treated DLEU1 Knockout Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: DLEU1 May Act As a Tumor Suppressor Gene in Pediatric BL

Ruxolitinib Significantly Prolongs Survival in Both a Primary Mediastinal B-Cell Lymphoma (PMBL) and Hodgkin Lymphoma (HL) Xenograft NSG Mouse Model: Ruxolitinib May be a Potential Adjuvant Agent in the Treatment of PMBL and of HL

Obinutuzumab (GA101) Significantly Inhibits Cell Proliferation and Induces Programmed Cell Death in Primary Mediastinal B-Cell Lymphoma (PMBL): Obinutuzumab May be a Future Targeted Agent for the Treatment of PMBL

Exogenous Overexpression Of DLEU1 Significantly Induces Programmed Cell Death and Inhibits Cell Proliferation In Burkitt Lymphoma (BL) and Sensitizes Rituximab (RTX) Resistant BL Cells To RTX Induced Apoptosis

Transcription Activator Like Effector Nucleases (TALENs) Mediated CD20 Gene Knockout Burkitt Lymphoma Model

Overexpression Of Deleted In Lymphocytic Leukemia 1 (DLEU1) Significantly Induces Programmed Cell Death and Inhibits Cell Proliferation In Primary Mediastinal B-Cell Lymphoma (PMBL): DLEU1 May Be a Tumor Suppressor Gene In a Subset Of Patients With PMBL

Sequence-Specific Talens-Induced DLEU1 Gene Disruption Significantly Suppresses Apoptosis and Increases Phosphorylation Of AKT and Ikba In Pediatric Burkitt Lymphoma (PBL): DLEU1 May Act As a Tumor Suppressor Gene In PBL

Obinutuzumab (GA101), a Novel Type II Glycoengineered CD20 Antibody, Significantly Induced Programmed Cell Death In Primary Mediastinal B-Cell Lymphoma (PMBL): Obinutuzumab May Be a Future Potential Targeted Agent For The Treatment Of PMBL

Transcription Activator-Like Effector Nucleases (TALENs)-Mediated Deletion Of MIR17HG In Burkitt Lymphoma Cells Decreases mTOR Pathway Activity and Increases Chemosensitivity

JAK1/JAK2 Inhibitor, Ruxolitinib Inhibits Cell Proliferation and Induces Apoptosis in Hodgkin Lymphomas (HL) and Primary Mediastinal B-Cell Lymphomas (PMBL)

Overexpression of Deleted Lymphocytic Leukemia 1 (DLEU1) Inhibits Proliferation of Burkitt Lymphoma (BL).

Talens-Mediated DLEU1 Gene Silencing in Burkitt Lymphoma (BL): Implication of Lncrna DLEU1 Gene As a Potential Tumor Suppressor Gene in BL.

Epigenetic Control of C/EBPa by Distant Synergic Regulatory Elements.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only